Open AccessA 65-Year-Old Male with Primary Central Nervous System Diffuse Large B-Cell Lymphoma on Nivolumab with Oral Mucositis and Targetoid Plaques
Author(s) -
Severine Cao,
Pooyan Rohani,
Rosalynn M. Nazarian,
Daniela Kroshinsky
Publication year - 2017
Publication title -
dermatopathology
Language(s) - English
Resource type - Journals
ISSN - 2296-3529
DOI - 10.1159/000481309
Subject(s) - medicine , mucositis , nivolumab , dermatology , erythema , lymphoma , diffuse large b cell lymphoma , adverse effect , histopathology , pathology , immunotherapy , chemotherapy , cancer
The development of programmed cell death-1 (PD-1) inhibitors has greatly improved patient outcomes in the treatment of a variety of advanced malignancies. These novel immunotherapies are not without adverse effects, the most common of which are dermatologic.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom